

Our Supply Operations Unit

Increased Capacity • Added Flexibility • Improved Compliance
Engineered to Meet Future Needs






Building 1:

- 5,000m² facility located in Worthing
- Serves as our Corporate Headquarters
- Houses our Research & Development facility
- Dedicated to the manufacture of POLLINEX® Quattro



Building 2:

- Self-sufficient facility
- Houses warehousing, manufacturing, inspection, labelling, packaging and despatch operations
- Contains 14 new manufacturing booths
- Fitted to the highest GMP standards



Our Supply Operations Unit

Increased Capacity • Added Flexibility • Improved Compliance
Engineered to Meet Future Needs

Our carefully planned programme of manufacturing readiness has culminated in the development of a world class manufacturing plant with the capacity to meet the internationally growing demand for POLLINEX® Quattro.

At Allergy Therapeutics our Supply Operations unit carries the responsibility for the manufacturing, inspection, packaging and distribution of the Company's entire injectable and sublingual vaccines and diagnostic product portfolio. Located in Worthing, on England's south coast, Supply Operations is based in a 5,000m² facility known as Building 1.

This licensed sterile manufacturing facility has the capability to process a tremendous range of lyophilised, aseptically filled and terminally sterilised parenteral products. As Allergy Therapeutics Corporate Headquarters, the site also serves the Company's Research & Development, Science & Quality Assurance, Finance and Administrative departments.

To meet the growing demand for our Company's products, Supply Operations works continually towards four key business aims:

- Increase capacity and flexibility.
- Introduce a new POLLINEX® Quattro manufacturing capability.
- Gain formal FDA approval of the manufacturing plant in time for product launches.
- Support the growth of the core business.

Reaching these goals is no small task and Supply Operations has therefore been underpinned by a capital investment programme of over €7.4 million to be spent over the next three years. This is the largest ever investment in allergy vaccine manufacturing in the United Kingdom and one of the largest ever worldwide.



In today's rapidly growing and constantly evolving global markets, flexible and responsive manufacturing are essential to meeting client demands. High capacity facilities and specialised staff are fundamental to realising this, and when they are combined with a passion for business, truly remarkable advances in production can be achieved.

Furthering our goal of reaching optimal capacity and flexibility in manufacturing, we have expanded into a second facility which has been fitted to the highest GMP standards. Building 2 has recently become the core of our named patient products business, allowing Building 1 to be refurbished for the dedicated manufacture of POLLINEX® Quattro.

This investment brings with it other unique advantages.

Increased capacity:

- Nearly 100% increase in our capacity to supply products has been achieved. Building 1 had 12 manufacturing booths. Building 2 will have 14 new booths, while eight booths will be retained in Building 1.
- We have also recruited and trained an additional eight manufacturing operatives, specialists who will help us to meet peak season demands.

Added flexibility:

- GMP regulations require that all pharmaceutical manufacturing facilities perform essential maintenance, calibration and qualification of facilities and utilities twice yearly. Previously, this necessitated a mandatory shutdown of all 12 manufacturing booths in Building 1, leading to disruptions in our product supply.

- With the commissioning of Building 2, we will be able to alternate these shutdowns, allowing us to constantly maintain supply to the physicians and patients we serve.

Improved compliance:

- Building 2 will become a self-sufficient facility, including warehousing, manufacturing, inspection, labelling, packaging and despatch operations.
- We are also investing in our people, providing for both new staff and development training for our current employees.
- The €7.4 million investment includes the addition of in-booth particulate monitoring and video monitoring of all operations, contributing to a state of the art facility.

Engineered ability to react to future needs:

- The new parenteral manufacturing facility in Building 2 is modular by design. Combined with the specialist skills of our experienced staff, this will enable us to react immediately to surges in product demand or shifts in product mix, making sure that customer stock is always kept full and orders delivered on time.




Advantages of investment in our buildings

Increased capacity

Added flexibility

Improved compliance

Engineered to Meet Future Needs



Aligned to this growth strategy is the ongoing recruitment of talented individuals with the scientific knowledge and laboratory skills needed to work in a highly regulated, aseptic parenteral manufacturing environment. The exceptional quality and work ethic of our employees is the foundation on which our continued growth is planned and will allow us to be ready for future product launches.

In addition to our manufacturing capability, we have a highly effective and responsive supply chain that includes an integrated Enterprise Resource Planning system, a Customer Order Management and Sales Support Operation, and a Planning and Purchasing function. Supporting both the Supply Chain and Manufacturing teams is a highly effective Information Technology team that provides our personnel with the cutting edge they rely on to achieve their objectives and meet the needs of our customers.

Collectively, the systems and people employed are able to deliver multiple distribution models, accommodating billing and payment systems and a rapid, controlled, turnaround of orders. Supplementing this, we use established, tried and tested cold chain distribution channels throughout Europe to ensure that the high quality products we make reach our discerning customers safely and on time.

Our Supply Operations strategy is already working, delivering considerable business benefits, including a significant turnaround in Customer Service performance. As Allergy Therapeutics continues to grow and develop its worldwide business, Supply Operations will remain the heart of the Company's activities, delivering novel treatments that will revolutionise and advance allergy patient care.

Allergy Therapeutics plc
Dominion Way
Worthing
West Sussex
BN14 8SA

T: +44 (0)1903 844720

F: +44 (0)1903 844726

www.allergytherapeutics.com
